IMPROVE KEY CLINICAL OUTCOMES BY TARGETING LUPUS NEPHRITIS WITH BENLYSTA

IMPROVE KEY CLINICAL OUTCOMES BY TARGETING LUPUS NEPHRITIS WITH BENLYSTA

Icon: #1

PRESCRIBED BIOLOGIC
APPROVED FOR LUPUS
  AND LUPUS NEPHRITIS1

Icon: Checklist

BENLYSTA improved key clinical outcomes in lupus nephritis2

VIEW LUPUS
NEPHRITIS DATA

TARGETED THERAPY FOR YOUR PATIENTS
WITH LUPUS AND LUPUS NEPHRITIS

Icon: Targets disease

Targets underlying disease3,4

SEE THE MOA
Icon: Checkmark

Improves key clinical outcomes2,5-7

Icon: Silhouette with flares

In lupus:

VIEW LUPUS DATA
Icon: Kidneys

In lupus nephritis:

VIEW LUPUS
NEPHRITIS DATA
Icon: Organ damage progression

Reduction of organ
damage progression8

VIEW ORGAN
DAMAGE DATA
Icon: Silhouette

Established safety consistent in diverse patient populations over 8 clinical trials

SEE SAFETY PROFILE

BENLYSTA IS THE FIRST AND ONLY APPROVED LUPUS TREATMENT DESIGNED TO TARGET BLyS, AN UNDERLYING CAUSE OF LUPUS AND LUPUS NEPHRITIS3,4,9-11

How Benlysta Works
  1. BENLYSTA is a human IgG1λ monoclonal antibody that blocks the binding of soluble BLyS, a B-cell survival factor, to its receptor on B cells.

    This inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.
  2. BENLYSTA does not directly bind to B cells and does not directly deplete B-cell populations.10,12

The clinical relevance of these results has not been definitively established.

MEET PATIENTS WITH LUPUS NEPHRITIS WHO COULD BENEFIT FROM BENLYSTA

img img

34 years old
Recently diagnosed with lupus nephritis

MEET ASHLEY
img img

38 years old
A patient with lupus nephritis and active disease

MEET DANIEL
Icon: Autoinjector

BENLYSTA Autoinjector: preferred over BENLYSTA IV by 3 out of 4 patients with lupus1,13*

A once-weekly dosing option with at-home convenience

Icon: Publications

Learn about the data in patients with lupus

View the Trial Data

Target lupus and lupus nephritis with BENLYSTA now